Nanjing Hicin Pharmaceutical Co.Ltd(300584) : Gf Securities Co.Ltd(000776) On Nanjing Hicin Pharmaceutical Co.Ltd(300584) Issuance sponsorship for the issuance of A shares to specific targets

Gf Securities Co.Ltd(000776)

About

Nanjing Hicin Pharmaceutical Co.Ltd(300584) Issuance of A-shares to specific targets

of

Issue Sponsor Letter

Sponsor (Lead Underwriter)

August 2002

Statement

Gf Securities Co.Ltd(000776) and the sponsor representative specifically responsible for the securities offering project have issued this offering sponsor letter in accordance with the Company Law, the Securities Law and other relevant laws and regulations and the relevant provisions of the CSRC and the Shenzhen Stock Exchange, in good faith and with due diligence, and in strict accordance with the business rules, industry practice norms and code of ethics established by law, and guarantee the truthfulness, accuracy and completeness of this offering sponsor letter and its annexes. We guarantee the authenticity, accuracy and completeness of this Offering Sponsor Letter and its annexes.

Unless otherwise specified, the terms used in this Offering Sponsor Letter shall have the same meaning as in the Prospectus for the Issue of A Shares to Certain Persons.

Table of Contents

Statement …… 1 Table of Contents …… 2 Section I. Basic information of the securities issue …… 3 I. The sponsor of this securities issue …… 3 II. The staff of the sponsor of this securities issue …… 3 III. Basic information of the issuer …… 3 IV. The relationship between the sponsor organization and the issuer for this securities issue …… 7 V. Internal audit procedures and kernel opinions of the sponsor …… 8 Section II. Commitments of the sponsor …… 11 Section III. Recommendation of the sponsor institution on the securities issuance …… 13 I. Recommendation conclusion of this sponsor organization on this securities issue …… 13 II. Procedures performed for this securities offering …… 13 III. The securities issue complies with the stipulated conditions of issue …… 13 IV. Main risks of the issuer …… 18 V. Evaluation of the development prospects of the issuer …… 23 VI. Other matters requiring clarification …… 24

Section I. Basic information of the securities issue

I. The sponsor of the securities issue

Gf Securities Co.Ltd(000776) (hereinafter referred to as ” Gf Securities Co.Ltd(000776) “, “the Sponsor” or “the Sponsor”). II. Staff of the sponsor organization for this securities issue

(I) Name of the sponsor representative in charge of the securities issue and his practice

Lin Min, sponsor representative, master of economic law, with legal professional qualification, joined Gf Securities Co.Ltd(000776) in 2014, has engaged in investment banking quality control work; has been responsible for or participated in Jinzhong automobile IPO project, Hefei Lifeon Pharmaceutical Co.Ltd(003020) IPO project, Guangdong Taiantang Pharmaceutical Co.Ltd(002433) Group deliverable bond project, etc., has rich experience in investment banking business.

Huang Sheng, sponsor representative, master of finance, has participated in Shanghai Medicilon Inc(688202) science and technology innovation board IPO project, Boji Medical Technology Co.Ltd(300404) issuance of A shares to specific objects project, Dongxing Medical directed issue project, Dongxing Medical major asset reorganization project, Shanghai Medicilon Inc(688202) issuance of A shares to specific objects in 2022 project, etc., has richer experience in investment banking business.

(Ⅱ) Name of the project co-organizer of this securities issue and its practice

Liu Bolun, Master of Engineering, has the qualification of Certified Public Accountant, legal professional qualification and tax accountant qualification, engaged in investment banking business in 2019, has participated in the IPO project of Yuda Baili, IPO project of CCTC, IPO project of Kang Hua Technology, etc., and has rich experience in investment banking business.

(III) Other members of the project team

Other members of the project team include Ren Zhenchao, Fei Cheng, Li Jianan, Zhang Xi, Li Yingwen and Tan Xu. III. Basic information of the issuer

(I) Basic information of the issuer

Company name Nanjing Hicin Pharmaceutical Co.Ltd(300584)

English name Nanjing Hicin Pharmaceutical Co.,Ltd.

Place of stock listing Shenzhen Stock Exchange

Stock short name Nanjing Hicin Pharmaceutical Co.Ltd(300584)

Stock code Nanjing Hicin Pharmaceutical Co.Ltd(300584)

Legal representative Cao Yu Ping

Registered capital: RMB 12,000000

Date of establishment January 15, 2003

Date of listing January 12, 2017

Registered address No. 1 Hengfa Road, Nanjing Economic and Technological Development Zone

Office Address No. 1 Hengfa Road, Nanjing Economic and Technological Development Zone

Contact Person Wang Li

Postal Code 210046

Internet website https:// www.hicin.cn.

Telephone number 02583241873

Fax No. 02585514865

Email [email protected]

Industry C27 Pharmaceutical Manufacturing

Manufacture of pharmaceuticals (operating under license) Development of pharmaceutical products; development and production of plant extracts; sales of self-produced products; import and export trade of pharmaceuticals and raw materials (in accordance with the relevant national regulations). (Projects that are subject to approval by the relevant authorities before commencing business activities)

Type of issuance of A shares to specific targets

(II) Issuer’s share capital structure and top ten shareholders

1. Share capital structure of the Issuer

As of March 31, 2022, the share capital structure of the Issuer is as follows.

Type of shares Number of shares held (shares) Shareholding ratio

I. Shares with limited sale 55,954749 46.63%

1. Shares held by the state – –

2. Shares held by state-owned legal persons – –

3、Other domestic shares 55,954749 46.63%

Of which: Shares held by domestic legal persons – –

Shares held by other domestic natural persons 55,954749 46.63%

4. Foreign shares – –

Of which: Shares held by foreign legal persons – –

Shares held by foreign natural persons – –

Shares with unlimited sales conditions 64,045251 53.37%

1. RMB ordinary shares 64,045251 53.37%

2、Domestic listed foreign shares – –

3、Overseas-listed foreign shares – –

4、Other – –

3. Total number of shares 1200 Ping An Bank Co.Ltd(000001) 00%

2. Shareholdings of the top ten shareholders of the issuer

As of March 31, 2022, the shareholdings of the top ten shareholders of the Issuer were as follows.

Number of shares held Number of shares held for limited sale Number of shares held for unlimited sale Number of shares held for limited sale (shares) (shares)

1 Cao Yu Ping Domestic natural person 42.08% 50,491306 37,868479 12,622827

2 Jiang Xiaoqun Domestic natural person 9.98% 11,973913 8,980435 2,993478

3 Liu Xiaoquan, a domestic natural person 6.65% 7,982608 5,986956 1,995652

4 Yao Xiaomin Domestic natural person 3.33% 3,991305 2,993479 997826

Tibet Trust Co.

5 Tibet Trust – Zhi Zhen 33 Others 1.77% 2,127730 – 2,127730 Pooled Funds Trust Plan

6 Jiang Jinyuan Domestic natural person 0.88% 1,053450 – 1,053450

7 Mao Youcong Domestic natural person 0.73% 872100 – 872100

8 Wei Juan Yi, a domestic natural person 0.71% 848224 – 848224

9 Wei Wei, a domestic natural person 0.59% 710658 – 710658

10 # Song Zirong, a domestic natural person 0.56% 671100 – 671100

Total 67.28% 80,722394 55,829349 24,893045

Note: # represents shares held through credit accounts.

(III) Successive fund-raising, cash dividends and changes in net assets of the issuer

Since the listing, the Company’s historical fund raising, cash dividends and changes in net assets are as follows.

Unit: RMB million

25,208.00 (as of June 30, 2016) attributable to the parent company at the end of the most recent period prior to the initial public offering

Net assets of

Issuance time Issuance category Net amount raised

Successive fund-raising

January 2017 Initial public offering of shares 19,845.70

Accumulated cash distribution after the initial offering 11,900.00

Attributable to the Parent Company 96,286.96 at the end of the most recent period prior to the issue (as of March 31, 2022)

Net assets of the Company

Note: The Issuer’s profit distribution plan for the year 2021: a cash dividend of RMB2.5 (including tax) per 10 shares to all shareholders based on the Company’s share capital of 120000000 shares as of December 31, 2021, for a total cash dividend of RMB30,000000 (including tax). The above profit distribution plan has been approved by the shareholders of the Issuer for the year 2021.